| Public Act* No. | Description | Effective Date |
|---|---|---|
| Prescribing Controlled Substances | ||
| PA 247 of 2017 | Requires prescribers to have a bona fide prescriber-patient relationship in order to prescribe a controlled substance. | Jan 2019 |
| PA 251 of 2017 | Limits acute pain opioid prescriptions to 7-day period and supply. Allows pharmacists to partially fill a controlled substance (Schedule 2) prescription. | July 2018 |
| PA 248 of 2017 | Requires prescriber to obtain and review a MAPS report prior to prescribing or dispensing a controlled substance prescription exceeding a 3-day supply. | June 2018 |
| PA 246 of 2017 | Requires prescriber to educate the patient and have an attestation form signed prior to issuing a control substance prescription. | June 2018 |
| Overdose Treatment | ||
| PA 250 of 2017 | Requires professionals treating a patient for an opioid-related overdose to provide information on Substance Use Disorder (SUD) treatment services. | March 2018 |
| Medication Assisted Treatment | ||
| PA 19 of 2022 | Removes prior authorization on medications used to treat opioid use disorder, including buprenorphine, for patients with Michigan Medicaid. | June 2022 |
| DHHS (Federal) | Requires prescribers to obtain an X-waiver before prescribing buprenorphine, but requirements for training and the provision of psychosocial services have been removed. | April 2021 |
| Naloxone | ||
| PA 176 of 2022 | Allows the distribution of naloxone community-based organizations, such as a nonprofit organizations or social service providers, under a standing order and protects from liability. | July 2022 |
| PA 39 of 2019 | Allows agencies to purchase and possess an opioid antagonist and distribute it to a trained employee. Allows the employee to administer it to an individual who they believe is experiencing an opioid-related overdose. | Sept 2019 |
| PA 383 of 2016 | Allows pharmacists to dispense Naloxone without an individual prescription and without identifying a particular patient (aka Naloxone standing order). | March 2017 |
| PA 307 of 2016 | Protects from liability individuals who administer naloxone in good faith to someone whom they believe to be suffering an opioid-related overdose. | Jan 2017 |
| Non-Opioid Directive | ||
| PA 42, PA 43, PA 44 of 2022 | Requires insurer to provide non-opioid directive form upon enrollment/renewal; requires insurer to post form on website; requires hospital to post form on website. | March 2022 |
| PA 41 of 2022 | Provides exception to non-opioid directive that allows certain prescribers to administer opioids for intraoperative use. | March 2022 |
| PA 554 of 2018 | Allows patients to fill out a state form that directs health professionals and emergency medical services personnel to not administer opioids to them. | March 2019 |
Last updated October 2022.
*A public act is a bill that has been approved by the Legislature and signed into law. This version is as originally passed and does not include updates from subsequent legislation (see Michigan Compiled Laws).
**Naloxone, also known by its brand name Narcan®, is a medication intended for the reversal of an overdose that occurs after consumption or use of one or more opioids or opioid-related substances.
Cite this work:
OPEN: Opioid Prescribing Engagement Network. (2022). Current Michigan Opioid Policy. Retrieved from https://doi.org/10.56137/OPEN.000082